Gene: SLC2A13

114134
HMIT
solute carrier family 2 member 13
protein-coding
12q12
Ensembl:ENSG00000151229 MIM:611036 Vega:OTTHUMG00000059743 UniprotKB:Q96QE2
NC_000012.12
PubMed
1   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.277e-1 (AD)  4.320e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7135349chr12:39890752 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSRNP30.961
FRRS1L0.955
CACNA2D10.948
GABRA40.945
CHL10.945
FGF140.944
TRUB10.941
SCAMP10.937
ELOVL40.935
SCN2A0.935

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.601
MAGEA12-0.512
RUNX3-0.504
CNN2-0.5
SYDE1-0.497
FLT3LG-0.495
HEY2-0.493
GJA4-0.482
AGTRAP-0.48
RNF135-0.48

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of SLC2A13 mRNA"28903501
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of SLC2A13 mRNA"20453058
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of SLC2A13 mRNA29067470
D020106AcrylamideAcrylamide results in decreased expression of SLC2A13 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SLC2A13 mRNA27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SLC2A13 mRNA16483693
D001280AtrazineAtrazine results in decreased expression of SLC2A13 mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SLC2A13 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of SLC2A13 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SLC2A13 mRNA"19150397
C006780bisphenol Abisphenol A results in increased expression of SLC2A13 mRNA29275510
C006780bisphenol Abisphenol A results in decreased expression of SLC2A13 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of SLC2A13 gene28505145
D002104CadmiumCadmium results in decreased expression of SLC2A13 mRNA26187450
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of SLC2A13 mRNA17484886
D004390ChlorpyrifosChlorpyrifos results in decreased expression of SLC2A13 mRNA18668222
C012843cinnamic aldehydecinnamic aldehyde results in increased expression of SLC2A13 mRNA19524605
D016572CyclosporineCyclosporine results in increased expression of SLC2A13 mRNA20106945
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of SLC2A13 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of SLC2A13 mRNA27392435
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of SLC2A13 mRNA23649840
D004397FonofosFonofos results in decreased methylation of SLC2A13 promoter22847954
C001277geldanamycingeldanamycin results in increased expression of SLC2A13 mRNA26705709
D017313FenretinideFenretinide results in decreased expression of SLC2A13 mRNA28973697
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of SLC2A13 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of SLC2A13 mRNA24796395|2675264
D007854LeadLead affects the expression of SLC2A13 mRNA28903495
D008345ManganeseManganese results in increased expression of SLC2A13 mRNA17175027
C025340manganese chloridemanganese chloride results in increased expression of SLC2A13 mRNA17175027
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SLC2A13 mRNA23103053
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of SLC2A13 mRNA23649840
C016096N-(1,3-dimethylbutyl)-N'-phenyl-1,4-phenylenediamine"SLC2A13 gene SNP affects the susceptibility to N-(1,3-dimethylbutyl)-N'-phenyl-1,4-phenylenediamine"25622337
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of SLC2A13 mRNA27935865
D010278ParathionParathion results in decreased methylation of SLC2A13 promoter22847954
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of SLC2A13 mRNA27153767
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of SLC2A13 mRNA26272509
D010936Plant ExtractsPlant Extracts results in increased expression of SLC2A13 mRNA23557933
D011441PropylthiouracilPropylthiouracil results in decreased expression of SLC2A13 mRNA24780913
C012568terbufosterbufos results in decreased methylation of SLC2A13 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to SLC2A13 gene]28213091
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SLC2A13 mRNA28213091
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of SLC2A13 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC2A13 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SLC2A13 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased methylation of SLC2A13 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of SLC2A13 mRNA19101580|2317975
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SLC2A13 gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of SLC2A13 mRNA26682919
C111237vorinostatvorinostat results in increased expression of SLC2A13 mRNA27188386
C581157XL147[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of SLC2A13 mRNA27935865

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005351carbohydrate:proton symporter activity-IBA21873635  
GO:0005355glucose transmembrane transporter activity-IBA21873635  
GO:0005366myo-inositol:proton symporter activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0015798myo-inositol transport-TAS-  
GO:0046323glucose import-IBA21873635  
GO:1902600proton transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-382551Transport of small moleculesTAS
R-HSA-425366Transport of bile salts and organic acids, metal ions and amine compoundsTAS
R-HSA-425407SLC-mediated transmembrane transportTAS
R-HSA-429593Inositol transportersTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
22763023An exploratory analysis on gene-environment interactions for Parkinson disease. (2012 Oct)Gao JNeurobiol Aging